Health care stocks were flat to higher premarket Monday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) up 0.3%.
Novo Nordisk (NVO) shares were down more than 15% after the company said its weight-loss treatment CagriSema failed to achieve the primary endpoint of demonstrating that it wasn't inferior to Eli Lilly's (LLY) tirzepatide in a late-stage Redefine 4 study.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments